FDA Approves New Lymphoma Treatment, Rituximab
The study showed that when taking the drug, patients progression-free rate of survival increased nearly 200 percent for those who continued medicating with rituximab.
The study showed that when taking the drug, patients progression-free rate of survival increased nearly 200 percent for those who continued medicating with rituximab.